View up-to-date information on Cytokinetics Inc’s latest deals, number of deals and deal values, alongside insights into its key mergers and acquisitions.
Number of Deals
Deal Value ($M)
Latest Deals
| Announced Date | Headline | Deal Type | Acquirers/Investors/Surviving Entity | Issuer/Partner/Target |
|---|---|---|---|---|
| July 01, 2022 | Cytokinetics Prices Private Placement of 3.50% Convertible Senior Notes Due 2027 for USD450 Million | Debt Offering | - | Cytokinetics Inc |
| January 07, 2022 | Royalty Pharma Acquires Royalty Rights for Omecamtiv Mecarbil from Cytokinetics | Asset Transaction | Royalty Pharma Plc | Cytokinetics Inc |
| January 07, 2022 | Royalty Pharma Acquires Royalty Rights for Aficamten from Cytokinetics | Asset Transaction | Royalty Pharma Plc | Cytokinetics Inc |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
| 06 Apr 2021 | Lorem ipsum dolor sit amet, consectetur adipiscing elit | Eiusmod Tempor | Exercitation cillum velit | Exercitation cillum velit Tempor |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer